SC 13D/A 1 y40325sc13da.txt FINAL AMENDMENT TO SCHEDULE 13D 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (FINAL AMENDMENT)* AMYLIN PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 032346 10 8 (CUSIP Number) James J. Bergin, Esq. Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933 (723) 524-2383 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 28, 2000 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box. / / NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 6 Pages 2 SCHEDULE 13D ---------------------- ----------------- CUSIP NO. 032346 10 8 PAGE 2 OF 6 PAGES ---------------------- ----------------- ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson 22-1024240 ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / ------------------------------------------------------------------------------- 3 SEC USE ONLY ------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* AF ------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / / ------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey ------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER SHARES BENEFICIALLY -0- OWNED BY EACH REPORTING PERSON WITH --------------------------------------------------------- 8 SHARED VOTING POWER 3,105,857 --------------------------------------------------------- 9 SOLE DISPOSITIVE POWER -0- --------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 3,105,857 ------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,105,857 ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.94% ------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 3 SCHEDULE 13D ------------------------- ----------------- CUSIP NO. 032346 10 8 PAGE 3 OF 6 PAGES ------------------------- ----------------- ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson Development Corporation 22-2007137 ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / ------------------------------------------------------------------------------- 3 SEC USE ONLY ------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC ------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / / ------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey ------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER SHARES BENEFICIALLY -0- OWNED BY EACH REPORTING PERSON WITH --------------------------------------------------------- 8 SHARED VOTING POWER 3,105,857 --------------------------------------------------------- 9 SOLE DISPOSITIVE POWER -0- --------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 3,105,857 ------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,105,857 ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.94% ------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 4 CUSIP 032346 10 8 Page 4 of 6 Pages Final Amendment to Schedule 13D This Statement amends Item 5 of the Statement on Schedule 13D (the "Schedule 13D") relating to the shares of Common Stock, $.001 par value, of Amylin Pharmaceuticals, Inc., a Delaware corporation (the "Company") originally filed with the Securities and Exchange Commission on October 6, 1995 by Johnson & Johnson ("J&J") and Johnson & Johnson Development Corporation ("JJDC"), both New Jersey corporations. Capitalized terms used but not otherwise defined herein have the same meaning as in the Schedule 13D. Item 5. Interest in Securities of the Issuer: Item 5 is hereby amended by deleting the information in Item 5 of the Schedule 13D and substituting in lieu the information below. (a) As of the date hereof, J&J and JJDC each had beneficial ownership of an aggregate 3,105,857 shares of Common Stock, which constituted approximately 4.94% of the outstanding shares of Common Stock of the Company. The percentage amount set forth above is based upon the number of shares of Common Stock issued and outstanding as of August 4, 2000, as reported in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2000. (b) J&J and JJDC each have shared power to vote and shared power to dispose of all shares described in paragraph (a) above. (c) There were no transactions in the Common Stock of the Company effected by J&J during the past sixty days. Set forth below is a list of the transactions in the Common Stock of the Company effected by JJDC since Amendment No. 4 to the Schedule 13D was filed. Each transaction was a sale of Common Stock affected over the counter through a broker:
TRADE DATE # SHARES PRICE/ SHARE ------------------------------------------------------------------------------ 02/24/00 17,500 $13.2500 02/28/00 5,000 $14.0000 02/29/00 40,000 $14.0156 03/01/00 140,000 $15.2143 03/03/00 85,000 $16.5662 03/06/00 100,000 $17.3969 03/07/00 15,000 $17.8750 06/21/00 25,000 $12.5000 06/22/00 25,000 $13.5000
5 CUSIP 032346 10 8 Page 5 of 6 Pages 08/14/00 5,000 $14.0625 08/16/00 10,000 $13.5938 08/17/00 5,000 $13.6250 08/21/00 10,000 $13.6875 08/22/00 10,000 $14.0125 08/23/00 17,500 $14.1964 08/24/00 52,500 $14.0381 08/25/00 65,000 $13.9538 08/28/00 20,000 $13.9375 08/29/00 22,500 $13.4167 08/30/00 10,000 $13.3750 08/31/00 45,000 $13.5000 09/01/00 30,000 $13.5938 09/05/00 25,000 $14.0000 09/06/00 27,500 $13.3977 09/07/00 50,000 $13.6363
To the best knowledge of J&J and JJDC, no director or executive officer of J&J or JJDC beneficially owns any shares of Common Stock or other securities of the Company. Neither J&J nor JJDC is aware of any other transaction in such securities during the past sixty (60) days by any of its executive officers or directors. (d) Not applicable. (e) JJDC sold approximately one percent (1%) of the Common Stock on August 28, 2000. The Reporting persons ceased to be the owner of more than five percent (5%) of the Common Stock on September 7, 2000, when the percentage of Common Stock beneficially held by the Reporting Persons was reduced to four point nine four percent (4.94%) of the outstanding Common Stock. The percentage amounts set forth above are based upon the number of shares of Common Stock issued and outstanding as of August 4, 2000, as reported in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2000. Consequently, this is a final amendment to the Schedule 13D. 6 CUSIP 032346 10 8 Page 6 of 6 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JOHNSON & JOHNSON Dated: September 12, 2000 By /s/ M. Ullmann -------------------------------- Name: Michael Ullmann Title: Secretary JOHNSON & JOHNSON DEVELOPMENT CORPORATION Dated: September 12, 2000 By /s/ J. J. Bergin -------------------------------- Name: James J. Bergin Title: Assistant Secretary